Alzeca Biosciences develops imaging compounds to diagnose Alzheimer's disease at the earliest stages. Early detection of Alzheimer's is critical as disease pathology begins to accumulate 10+ years prior to cognitive onset of the disease. As a result, early detection of Alzheimer's pathology offers the patient an opportunity to take counteractive measures at a point where the disease may still be treatable.

NeuroVision Imaging is developing retinal imaging technology for early detection and monitoring of Alzheimer's disease.

Neurotrack is a digital medicine solution for Alzheimer's disease, giving people direct access to the scientifically validated digital diagnostic and therapeutic to delay or prevent memory health conditions.

Darmiyan develops fully automated proprietary software that inputs human brain MRIs and produces maps that detect Alzheimer's disease up to fifteen years before symptoms. Its mission is to create a fast, non-invasive, inexpensive, precise, and globally accessible tool for brain health screening and monitoring. Darmiyan's technology provides a platform for presymptomatic diagnosis of neurodegenerative disorders, with precise quantification and localization of microscopic abnormality in the brain.

ADispell is a pharmaceutical development company with technology related to Alzheimers, cognition-loss disease, drug addiction, and other CNS areas. Three lead compounds have been identified for this platform technology and in vivo experiments have produce clear evidence of improved cognition and learning in impaired animals. Our team will continue pre-clinical work with the goal of licensing our development to a pharma partner. These deals have closed for $100s of millions of dollars.

Cytox is developing a diagnostic test and therapeutic cures for Alzheimer's Disease. The company is a university spin-out based on academic research into the role of the cell cycle in neuro-degenerative diseases.